(Q47993135)

English

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.

scientific article published on 22 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. (English)

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

phase II clinical trial

0 references

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

12

object named as

Carl H June

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

Bruce L. Levine

7

object named as

Bruce L Levine

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

author name string

Christina S Chu

1

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

Jean Boyer

2

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

Daniel S Schullery

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

Phyllis A Gimotty

4

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

Victoria Gamerman

5

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

James Bender

6

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

Stephen C Rubin

9

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

Mark A Morgan

10

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

Robert H Vonderheide

11

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

publication date

22 October 2011

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

61

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

5

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

629-641

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

https://scigraph.springernature.com/pub.10.1007/s00262-011-1081-8

0 references

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Immunologic approaches to ovarian cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

The impact of T-cell immunity on ovarian cancer outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Immunomodulatory effects of docetaxel on human lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Dendritic cells as therapeutic vaccines against cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Telomerase as a universal tumor-associated antigen for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

THE ANTINEOPLASTIC DRUG PACLITAXEL HAS IMMUNOSUPPRESSIVE PROPERTIES THAT CAN EFFECTIVELY PROMOTE ALLOGRAFT SURVIVAL IN A RAT HEART TRANSPLANT MODEL1

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1081-8

21 January 2018

Identifiers

10.1007/S00262-011-1081-8

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/22021066

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47993135&oldid=1790285477"